ERK-IN-6

Cat. No.: HY-151934 Molecular Formula: $C_{19}H_{18}BrN_3O_3S$

Molecular Weight: 448.33

Target: Apoptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

DescriptionERK-IN-6 (compound 6g) is an potent anti-proliferation agent against esophageal squamous cell carcinoma (ESCC). ERK-IN-6 induces cell apoptosis via ERK pathway. ERK-IN-6 can be used for the research of ESCC^[1].

IC₅₀ & Target IC50: 16.8 μM (KYSE-30), 10.07 μM (KYSE-150), 13 μM (HET-1A), 202.2 μM (NES-G4T)^[1]

In Vitro ERK-IN-6 (0-10 μM; 72 h) inhibits cell proliferation of ESCC cells^[1].

ERK-IN-6 (10 μ M; 48-72 h) induces cell apoptosis through the ERK pathway^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	KYSE-30, KYSE-150, HET-1A and NES-G4T cell lines
Concentration:	0-10 μΜ
Incubation Time:	72 hours
Result:	Dose-dependently inhibited cell proliferation of KYSE-30, KYSE-150, HET-1A and NES-G4T cells with IC $_{50}$ values of 16.8, 10.07, 13 and 202.2 μ M, respectively.

Apoptosis Analysis^[1]

Cell Line:	KYSE-30 and KYSE-150 cell lines
Concentration:	10 μΜ
Incubation Time:	48 and 72 hours
Result:	Induced KYSE-30 and KYSE-150 cell apoptosis with the loss of nuclei integrity at 72 h.

Western Blot Analysis^[1]

Cell Line:	KYSE-150 and NES-G4T cell lines
Concentration:	10 μΜ
Incubation Time:	4, 8 and 12 hours

Result:	Time-dependently down regulated pERK.

REFERENCES

[1]. Marian NA, et al. Novel thiazolidines of potential anti-proliferation properties against esophageal squamous cell carcinoma via ERK pathway. European Journal of Medicinal Chemistry. 24 November 2022, 114909.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA